MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 4.3% – Here’s What Happened

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)’s stock price was down 4.3% on Thursday . The company traded as low as $1.09 and last traded at $1.10. Approximately 69,365 shares traded hands during trading, a decline of 96% from the average daily volume of 1,921,606 shares. The stock had previously closed at $1.15.

MIRA Pharmaceuticals Stock Performance

The company has a market capitalization of $18.22 million, a PE ratio of -1.96 and a beta of 2.31. The company’s 50-day simple moving average is $1.12 and its 200-day simple moving average is $1.23.

Hedge Funds Weigh In On MIRA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in MIRA. Two Sigma Investments LP acquired a new position in MIRA Pharmaceuticals in the 4th quarter valued at about $28,000. International Assets Investment Management LLC acquired a new position in shares of MIRA Pharmaceuticals in the fourth quarter valued at approximately $29,000. Northern Trust Corp increased its holdings in shares of MIRA Pharmaceuticals by 50.9% in the fourth quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after purchasing an additional 10,238 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth approximately $52,000. Finally, Virtu Financial LLC acquired a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth $72,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.